Showing results (261-270 of 310) with videos related to

Sort By:
Pageof 31
Annals of the Rheumatic Diseases|August 21, 2025
EULAR recommendations for a core dataset to support clinical care and translational and observational research in systemic lupus erythematosusJohanna Mucke, George Bertsias, Martin Aringer, et al.
Arthritis Care & Research|January 26, 2016
The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic SclerosisDinesh Khanna, Veronica J Berrocal, Edward H Giannini, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 26, 2016
The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic SclerosisDinesh Khanna, Veronica J Berrocal, Edward H Giannini, et al.
The Lancet. Rheumatology|January 22, 2024
Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): open-label, long-term extension of a phase 2b, randomised, placebo-controlled trialOliver Distler, Yannick Allanore, Christopher P Denton, et al.
Annals of the Rheumatic Diseases|March 31, 2019
2019 update of the EULAR recommendations for the management of systemic lupus erythematosusAntonis Fanouriakis, Myrto Kostopoulou, Alessia Alunno, et al.
Zeitschrift Fur Orthopadie Und Unfallchirurgie|October 20, 2017
Indication Criteria for Total Knee Arthroplasty in Patients with Osteoarthritis - A Multi-perspective Consensus StudyJochen Schmitt, Toni Lange, Klaus-Peter Günther, et al.
Lupus Science & Medicine|May 21, 2021
What are the topics you care about making trials in lupus more effective? Results of an Open Space meeting of international lupus expertsJohanna Mucke, Marta Alarcon-Riquelme, Jeanette Andersen, et al.
Annals of the Rheumatic Diseases|April 18, 2020
Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trialDinesh Khanna, Yannick Allanore, Christopher P Denton, et al.
Rheumatology (Oxford, England)|March 9, 2024
Biomarker analysis from the phase 2b randomized placebo-controlled trial of riociguat in early diffuse cutaneous systemic sclerosisDinesh Khanna, Frank Kramer, Josef Höfler, et al.
Annals of the Rheumatic Diseases|March 30, 2020
2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritisAntonis Fanouriakis, Myrto Kostopoulou, Kim Cheema, et al.
Pageof 31